AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
STRUCTURE AND FUNCTIONS OF SOCIAL SUPPORT IN CANCER
Authors: LEHTOJARNSTEDT US OJANEN M KELLOKUMPULEHTINEN P
Citation: Us. Lehtojarnstedt et al., STRUCTURE AND FUNCTIONS OF SOCIAL SUPPORT IN CANCER, Psycho-oncology, 7(3), 1998, pp. 2054-2054
PSYCHOLOGICAL STRESS PROCESSES 3 MONTHS AFTER CANCER-DIAGNOSIS
Authors: LEHTOJARNSTEDT US OJANEN M KELLOKUMPULEHTINEN P
Citation: Us. Lehtojarnstedt et al., PSYCHOLOGICAL STRESS PROCESSES 3 MONTHS AFTER CANCER-DIAGNOSIS, Psycho-oncology, 7(3), 1998, pp. 2055-2055
DOSAGE OF ADJUVANT G-CSF (FILGRASTIM) SUPPORTED FEC POLYCHEMOTHERAPY BASED ON EQUIVALENT HEMATOLOGICAL TOXICITY IN HIGH-RISK BREAST-CANCER PATIENTS
Authors: BERGH J WIKLUND T ERIKSTEIN B FORNANDER T BENGTSSON NO MALMSTROM P KELLOKUMPULEHTINEN P ANKER G BENNMARKER H WILKING N
Citation: J. Bergh et al., DOSAGE OF ADJUVANT G-CSF (FILGRASTIM) SUPPORTED FEC POLYCHEMOTHERAPY BASED ON EQUIVALENT HEMATOLOGICAL TOXICITY IN HIGH-RISK BREAST-CANCER PATIENTS, Annals of oncology, 9(4), 1998, pp. 403-411
HUMAN PLASMA ANTIOXIDANT CAPACITY DURING RADIOTHERAPY FOR LUNG-CANCER- A CLINICAL-STUDY
Authors: ERHOLA M NIEMINEN MM OJALA A METSAKETELA T KELLOKUMPULEHTINEN P ALHO H
Citation: M. Erhola et al., HUMAN PLASMA ANTIOXIDANT CAPACITY DURING RADIOTHERAPY FOR LUNG-CANCER- A CLINICAL-STUDY, Journal of experimental & clinical cancer research, 17(3), 1998, pp. 325-330
EFFECTS OF SURGICAL REMOVAL OF LUNG-CANCER ON TOTAL PLASMA ANTIOXIDANT CAPACITY IN LUNG-CANCER PATIENTS
Authors: ERHOLA M NIEMINEN MM KELLOKUMPULEHTINEN P HUUSARI H ALANKO K METSAKETELA T ALHO H
Citation: M. Erhola et al., EFFECTS OF SURGICAL REMOVAL OF LUNG-CANCER ON TOTAL PLASMA ANTIOXIDANT CAPACITY IN LUNG-CANCER PATIENTS, Journal of experimental & clinical cancer research, 17(2), 1998, pp. 219-225
SINGLE-CENTER EXPERIENCE OF PBSCT IN MALIGNANT-LYMPHOMAS AND SOLID TUMORS
Authors: LEHTINEN T KOIVUNEN E LEHTINEN M KELLOKUMPULEHTINEN P
Citation: T. Lehtinen et al., SINGLE-CENTER EXPERIENCE OF PBSCT IN MALIGNANT-LYMPHOMAS AND SOLID TUMORS, Bone marrow transplantation, 21, 1998, pp. 592-592
PLASMA PEROXYL RADICAL TRAPPING CAPACITY IN LUNG-CANCER PATIENTS - A CASE-CONTROL STUDY
Authors: ERHOLA M NIEMINEN MM KELLOKUMPULEHTINEN P METSAKETELA T POUSSA T ALHO H
Citation: M. Erhola et al., PLASMA PEROXYL RADICAL TRAPPING CAPACITY IN LUNG-CANCER PATIENTS - A CASE-CONTROL STUDY, Free radical research, 26(5), 1997, pp. 439-447
IFOSFAMIDE (IFO) IN THE TREATMENT OF METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER
Authors: KELLOKUMPULEHTINEN P LEHTINEN T TAMMELA T
Citation: P. Kellokumpulehtinen et al., IFOSFAMIDE (IFO) IN THE TREATMENT OF METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER, European journal of cancer, 33, 1997, pp. 128-128
CANCER-PATIENT INFORMATION AND SUPPORT
Authors: KESKINEN L SALMI E LEHTINEN K LEHTOJARNSTEDT US TASKINEN K KELLOKUMPULEHTINEN P
Citation: L. Keskinen et al., CANCER-PATIENT INFORMATION AND SUPPORT, European journal of cancer, 33, 1997, pp. 274-274
SINGLE-AGENT GEMCITABINE VERSUS CISPLATIN-ETOPOSIDE - EARLY RESULTS OF A RANDOMIZED PHASE-II STUDY IN LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG-CANCER
Authors: MANEGOLD C BERGMAN B CHEMAISSANI A DORNOFF W DRINGS P KELLOKUMPULEHTINEN P LIIPPO K MATTSON K VONPAWEL J RICCI S SEDERHOLM C STAHEL RA WAGENIUS G VONWALREE N TENBOKKELHUININK W
Citation: C. Manegold et al., SINGLE-AGENT GEMCITABINE VERSUS CISPLATIN-ETOPOSIDE - EARLY RESULTS OF A RANDOMIZED PHASE-II STUDY IN LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG-CANCER, Annals of oncology, 8(6), 1997, pp. 525-529
P53 EXPRESSION AND CELL-PROLIFERATION AS PROGNOSTIC FACTORS IN LARYNGEAL SQUAMOUS-CELL CARCINOMA
Authors: HIRVIKOSKI P KUMPULAINEN E VIRTANIEMI J JOHANSSON R HAAPASALO H MARIN S HALONEN P HELIN H RAITIOLA H PUKANDER J KELLOKUMPULEHTINEN P KOSMA VM
Citation: P. Hirvikoski et al., P53 EXPRESSION AND CELL-PROLIFERATION AS PROGNOSTIC FACTORS IN LARYNGEAL SQUAMOUS-CELL CARCINOMA, Journal of clinical oncology, 15(9), 1997, pp. 3111-3120
A PRACTICAL PROGNOSTIC INDEX FOR INOPERABLE NON-SMALL-CELL LUNG-CANCER
Authors: WIGREN T OKSANEN H KELLOKUMPULEHTINEN P
Citation: T. Wigren et al., A PRACTICAL PROGNOSTIC INDEX FOR INOPERABLE NON-SMALL-CELL LUNG-CANCER, Journal of cancer research and clinical oncology, 123(5), 1997, pp. 259-266
A RANDOMIZED STUDY OF GEMCITABINE MONOTHERAPY VERSUS ETOPOSIDE CISPLATIN IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG-CANCER/
Authors: MANEGOLD C DRINGS P VONPAWEL J RICCI S DORNOFF W VANWALREE N HUININK WT CHEMAISSANI A STAHEL P BERGMAN B WAGENIUS G SEDERHOLM C MATTSON K LIIPPO K KELLOKUMPULEHTINEN P
Citation: C. Manegold et al., A RANDOMIZED STUDY OF GEMCITABINE MONOTHERAPY VERSUS ETOPOSIDE CISPLATIN IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG-CANCER/, Seminars in oncology, 24(3), 1997, pp. 813-817
BIOMARKER EVIDENCE OF DNA OXIDATION IN LUNG-CANCER PATIENTS - ASSOCIATION OF URINARY 8-HYDROXY-2'-DEOXYGUANOSINE EXCRETION WITH RADIOTHERAPY, CHEMOTHERAPY, AND RESPONSE TO TREATMENT
Authors: ERHOLA M TOYOKUNI S OKADA K TANAKA T HIAI H OCHI H UCHIDA K OSAWA T NIEMINEN MM ALHO H KELLOKUMPULEHTINEN P
Citation: M. Erhola et al., BIOMARKER EVIDENCE OF DNA OXIDATION IN LUNG-CANCER PATIENTS - ASSOCIATION OF URINARY 8-HYDROXY-2'-DEOXYGUANOSINE EXCRETION WITH RADIOTHERAPY, CHEMOTHERAPY, AND RESPONSE TO TREATMENT, FEBS letters, 409(2), 1997, pp. 287-291
SERUM LEVELS OF INTERLEUKIN-2, INTERLEUKIN-6 AND INTERLEUKIN-8, SOLUBLE INTERLEUKIN-2 RECEPTOR AND INTERCELLULAR-ADHESION MOLECULE-1 DURINGTREATMENT WITH INTERLEUKIN-2 PLUS INTERFERON-ALPHA
Authors: VUORISTO MS KELLOKUMPULEHTINEN P LAINE S SOPPI E
Citation: Ms. Vuoristo et al., SERUM LEVELS OF INTERLEUKIN-2, INTERLEUKIN-6 AND INTERLEUKIN-8, SOLUBLE INTERLEUKIN-2 RECEPTOR AND INTERCELLULAR-ADHESION MOLECULE-1 DURINGTREATMENT WITH INTERLEUKIN-2 PLUS INTERFERON-ALPHA, Immunopharmacology and immunotoxicology, 18(3), 1996, pp. 337-354
EFFECTS OF ANTHRACYCLIN-BASED CHEMOTHERAPY ON TOTAL PLASMA ANTIOXIDANT CAPACITY IN SMALL-CELL LUNG-CANCER PATIENTS
Authors: ERHOLA M KELLOKUMPULEHTINEN P METSAKETELA T ALANKO K NIEMINEN MM
Citation: M. Erhola et al., EFFECTS OF ANTHRACYCLIN-BASED CHEMOTHERAPY ON TOTAL PLASMA ANTIOXIDANT CAPACITY IN SMALL-CELL LUNG-CANCER PATIENTS, Free radical biology & medicine, 21(3), 1996, pp. 383-390
PROPHYLACTIC FILGRASTIM (G-CSF) DURING MITOMYCIN-C, MITOXANTRONE, ANDMETHOTREXATE (MMT) TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED STUDY
Authors: MUHONEN T JANTUNEN I PERTOVAARA H VOUTILAINEN L MAICHE A BLOMQVIST C PYRHONEN S KELLOKUMPULEHTINEN P
Citation: T. Muhonen et al., PROPHYLACTIC FILGRASTIM (G-CSF) DURING MITOMYCIN-C, MITOXANTRONE, ANDMETHOTREXATE (MMT) TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED STUDY, American journal of clinical oncology, 19(3), 1996, pp. 232-234
LEUKEMIA-INHIBITORY FACTOR STIMULATES BREAST, KIDNEY AND PROSTATE-CANCER CELL-PROLIFERATION BY PARACRINE AND AUTOCRINE PATHWAYS
Authors: KELLOKUMPULEHTINEN P TALPAZ M HARRIS D VAN Q KURZROCK R ESTROV Z
Citation: P. Kellokumpulehtinen et al., LEUKEMIA-INHIBITORY FACTOR STIMULATES BREAST, KIDNEY AND PROSTATE-CANCER CELL-PROLIFERATION BY PARACRINE AND AUTOCRINE PATHWAYS, International journal of cancer, 66(4), 1996, pp. 515-519
LEUKEMIA INHIBITORY FACTOR BINDS TO HUMAN BREAST-CANCER CELLS AND STIMULATES THEIR PROLIFERATION
Authors: ESTROV Z SAMAL B LAPUSHIN R KELLOKUMPULEHTINEN P SAHIN AA KURZROCK R TALPAZ M AGGARWAL BB
Citation: Z. Estrov et al., LEUKEMIA INHIBITORY FACTOR BINDS TO HUMAN BREAST-CANCER CELLS AND STIMULATES THEIR PROLIFERATION, Journal of interferon & cytokine research, 15(10), 1995, pp. 905-913
LEUKEMIA INHIBITORY FACTOR (LIF) STIMULATES THE GROWTH OF HUMAN BREAST-CANCER CELLS
Authors: KELLOKUMPULEHTINEN P TALPAZ M KURZROCK R HARRIS D VAN Q ESTROV Z
Citation: P. Kellokumpulehtinen et al., LEUKEMIA INHIBITORY FACTOR (LIF) STIMULATES THE GROWTH OF HUMAN BREAST-CANCER CELLS, European journal of cancer, 31A, 1995, pp. 228-228
SOLUBLE IMMUNOLOGICAL PARAMETERS IN PATIENTS TREATED WITH INTERLEUKIN-2 (IL-2) PLUS INTERFERON-ALPHA (IFN)
Authors: VUORISTO MS KELLOKUMPULEHTINEN P
Citation: Ms. Vuoristo et P. Kellokumpulehtinen, SOLUBLE IMMUNOLOGICAL PARAMETERS IN PATIENTS TREATED WITH INTERLEUKIN-2 (IL-2) PLUS INTERFERON-ALPHA (IFN), European journal of cancer, 31A, 1995, pp. 590-590
ACTION OF RECOMBINANT INTERFERONS AND INTERLEUKIN-2 IN MODULATING RADIATION EFFECTS ON VIABILITY AND CYTOTOXICITY OF LARGE GRANULAR LYMPHOCYTES
Authors: HIETANEN T KELLOKUMPULEHTINEN P PITKANEN M
Citation: T. Hietanen et al., ACTION OF RECOMBINANT INTERFERONS AND INTERLEUKIN-2 IN MODULATING RADIATION EFFECTS ON VIABILITY AND CYTOTOXICITY OF LARGE GRANULAR LYMPHOCYTES, International journal of radiation biology, 67(2), 1995, pp. 119-126
COMBINED INTERFERON AND VINBLASTINE TREATMENT IN ADVANCED RENAL-CELL CANCER
Authors: KELLOKUMPULEHTINEN P JANTUNEN I FLANDER M JOHANSSON R NORDMAN E
Citation: P. Kellokumpulehtinen et al., COMBINED INTERFERON AND VINBLASTINE TREATMENT IN ADVANCED RENAL-CELL CANCER, Acta oncologica, 34(7), 1995, pp. 975-977
INTERMITTENT INTERFERON AND POLYCHEMOTHERAPY IN METASTATIC MELANOMA
Authors: VUORISTO MS GROHN P KELLOKUMPULEHTINEN P TURUNEN M JOENSUU H KUMPULAINEN E KORPELA M TIUSANEN K NEVANTAUS A
Citation: Ms. Vuoristo et al., INTERMITTENT INTERFERON AND POLYCHEMOTHERAPY IN METASTATIC MELANOMA, Journal of cancer research and clinical oncology, 121(3), 1995, pp. 175-180
A COMBINATION OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA IN THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA OR MELANOMA
Authors: VUORISTO M JANTUNEN I PYRHONEN S MUHONEN T KELLOKUMPULEHTINEN P
Citation: M. Vuoristo et al., A COMBINATION OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA IN THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA OR MELANOMA, European journal of cancer, 30A(4), 1994, pp. 530-532
Risultati: 1-25 | 26-26